125 related articles for article (PubMed ID: 38636892)
1. NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis.
Ji R; Wang Y; Pan D; Han J; Wang Y; Zheng S; Zhao W; Li X; Han C; Zhang L
Cancer Lett; 2024 Jun; 591():216893. PubMed ID: 38636892
[TBL] [Abstract][Full Text] [Related]
2. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma.
Liu Z; Wen J; Hu F; Wang J; Hu C; Zhang W
Cancer Sci; 2022 Feb; 113(2):432-445. PubMed ID: 34927311
[TBL] [Abstract][Full Text] [Related]
4. Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma.
Liu Z; Wang H; Hu C; Wu C; Wang J; Hu F; Fu Y; Wen J; Zhang W
Cell Death Dis; 2021 Feb; 12(2):164. PubMed ID: 33558476
[TBL] [Abstract][Full Text] [Related]
5. Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines.
Keremu A; Aimaiti A; Liang Z; Zou X
Cancer Chemother Pharmacol; 2019 Feb; 83(2):255-264. PubMed ID: 30430228
[TBL] [Abstract][Full Text] [Related]
6. CXCL8 promotes the invasion of human osteosarcoma cells by regulation of PI3K/Akt signaling pathway.
Jiang H; Wang X; Miao W; Wang B; Qiu Y
APMIS; 2017 Sep; 125(9):773-780. PubMed ID: 28736978
[TBL] [Abstract][Full Text] [Related]
7. NUCKS1, a LINC00629-upregulated gene, facilitated osteosarcoma progression and metastasis by elevating asparagine synthesis.
Zheng S; Ji R; He H; Li N; Han C; Han J; Li X; Zhang L; Wang Y; Zhao W
Cell Death Dis; 2023 Aug; 14(8):489. PubMed ID: 37528150
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.
Wang J; Hu C; Wang J; Shen Y; Bao Q; He F; Wang H; Gong L; Liu Z; Hu F; Liang J; Zhou Q; Wei L; Wen J; Zhang W
J Immunother; 2019; 42(9):321-330. PubMed ID: 31219973
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.
Liu Z; Wen J; Wu C; Hu C; Wang J; Bao Q; Wang H; Wang J; Zhou Q; Wei L; Shen Y; Zhang W
Aging (Albany NY); 2020 Jan; 12(2):1213-1236. PubMed ID: 31981455
[TBL] [Abstract][Full Text] [Related]
10. Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer.
Lin C; He H; Liu H; Li R; Chen Y; Qi Y; Jiang Q; Chen L; Zhang P; Zhang H; Li H; Zhang W; Sun Y; Xu J
Gut; 2019 Oct; 68(10):1764-1773. PubMed ID: 30661053
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice.
Duan XL; Guo JP; Li F; Xiu C; Wang H
Future Oncol; 2020 Aug; 16(24):1815-1824. PubMed ID: 32511016
[No Abstract] [Full Text] [Related]
13. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
14. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.
Liu X; He S; Wu H; Xie H; Zhang T; Deng Z
Environ Health Prev Med; 2019 Dec; 24(1):79. PubMed ID: 31864288
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.
Wang J; Hu F; Yu P; Wang J; Liu Z; Bao Q; Zhang W; Wen J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5127-5138. PubMed ID: 36348018
[TBL] [Abstract][Full Text] [Related]
16. Nutrients differentially regulate nucleobindin-2/nesfatin-1 in vitro in cultured stomach ghrelinoma (MGN3-1) cells and in vivo in male mice.
Mohan H; Ramesh N; Mortazavi S; Le A; Iwakura H; Unniappan S
PLoS One; 2014; 9(12):e115102. PubMed ID: 25506938
[TBL] [Abstract][Full Text] [Related]
17. MYLK4 promotes tumor progression through the activation of epidermal growth factor receptor signaling in osteosarcoma.
Yang M; Zhang T; Zhang Y; Ma X; Han J; Zeng K; Jiang Y; Wang Z; Wang Z; Xu J; Hua Y; Cai Z; Sun W
J Exp Clin Cancer Res; 2021 May; 40(1):166. PubMed ID: 33980265
[TBL] [Abstract][Full Text] [Related]
18. CXCR1/Akt signaling activation induced by mesenchymal stem cell-derived IL-8 promotes osteosarcoma cell anoikis resistance and pulmonary metastasis.
Du L; Han XG; Tu B; Wang MQ; Qiao H; Zhang SH; Fan QM; Tang TT
Cell Death Dis; 2018 Jun; 9(7):714. PubMed ID: 29915309
[TBL] [Abstract][Full Text] [Related]
19. Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice.
Yin SJ; Wang WJ; Zhang JY
Genet Mol Res; 2015 Nov; 14(4):14253-61. PubMed ID: 26600483
[TBL] [Abstract][Full Text] [Related]
20. CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to enhance the transcriptional activity of β-catenin/LEF1 complex via effects on chromatin remodeling.
Chen J; Liu G; Wu Y; Ma J; Wu H; Xie Z; Chen S; Yang Y; Wang S; Shen P; Fang Y; Fan S; Shen S; Fang X
Mol Cancer; 2019 Oct; 18(1):150. PubMed ID: 31665067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
